Single- and repeated-dose pharmacokinetics of ceftaroline in plasma and soft tissues of healthy volunteers for two different dosing regimens of ceftaroline fosamil

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 6, 2016, Pages 3617-3625

  Matzneller, Peter ^a   Lackner, Edith ^a   Lagler, Heimo ^a   Wulkersdorfer, Beatrix ^a   Österreicher, Zoe ^a   Zeitlinger, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE; CEFTAROLINE FOSAMIL; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; PPI-0903;

ADULT; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MICRODIALYSIS; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REPEATED DRUG DOSE; SINGLE DRUG DOSE; SOFT TISSUE; TIME TO MAXIMUM PLASMA CONCENTRATION; BLOOD; CHEMISTRY; DOSE CALCULATION; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; PHASE 3 CLINICAL TRIAL (TOPIC); SKELETAL MUSCLE; SUBCUTANEOUS TISSUE;

ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CEPHALOSPORINS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; HEALTHY VOLUNTEERS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MICROBIAL SENSITIVITY TESTS; MICRODIALYSIS; MIDDLE AGED; MUSCLE, SKELETAL; SUBCUTANEOUS TISSUE;

EID: 84973657509     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00097-16     Document Type: Article

References (32)

1. Corey GR, Wilcox MH, Talbot GH, Thye D, Friedland D, Baculik T. 2010. CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 65(Suppl 4):iv41-iv51. http://dx.doi.org/10.1093/jac/dkq254.
2. File TM, Jr, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J, Llorens L, Critchley IA, Thye DA. 2011. FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 66(Suppl 3):iii19-iii32. http://dx.doi.org/10.1093/jac/dkr096.
3. Low DE, File TM, Jr, Eckburg PB, Talbot GH, Friedland DH, Lee J, Llorens L, Critchley IA, Thye DA. 2011. FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community- acquired pneumonia. J Antimicrob Chemother 66(Suppl 3):iii33-iii44. http://dx.doi.org/10.1093/jac/dkr097.
4. Wilcox MH, Corey GR, Talbot GH, Thye D, Friedland D, Baculik T. 2010. CANVAS 2: the second phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 65(Suppl 4):iv53-iv65. http://dx.doi.org/10.1093/jac/dkq255.
5. Zhong NS, Sun T, Zhuo C, D'Souza G, Lee SH, Lan NH, Chiang CH, Wilson D, Sun F, Iaconis J, Melnick D. 2015. Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial. Lancet Infect Dis 15:161-171. http://dx.doi.org/10.1016/S1473-3099(14)71018-7.
6. Corey GR, Wilcox M, Gonzalez J, Jandourek A, Wilson D, Friedland HD, Das S, Iaconis JP, Dryden M. 2015. Ceftaroline fosamil (CPT-F) in patients with acute bacterial skin and skin structure infections (AB-SSSI) with systemic inflammatory signs: results across 3 pivotal studies using q8h or q12h, abstr L-839. Abstr 55th Intersci Conf Antimicrob Agents Chemother, San Diego, CA. American Society for Microbiology, Washington, DC.
7. Dryden M, Wilson D, Iaconis J, Gonzalez J. 2015. A phase III trial of ceftaroline fosamil 600 mg q8h versus vancomycin plus aztreonam in patients with cSSTI with systemic inflammatory response or underlying comorbidities, abstr O193. Abstr 25th Eur Conf Clin Microbiol Infect Dis, Copenhagen, Denmark.
8. Casapao AM, Davis SL, Barr VO, Klinker KP, Goff DA, Barber KE, Kaye KS, Mynatt RP, Molloy LM, Pogue JM, Rybak MJ. 2014. Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother 58:2541-2546. http://dx.doi.org/10.1128/AAC.02371-13.
9. Chaurasia CS, Muller M, Bashaw ED, Benfeldt E, Bolinder J, Bullock R, Bungay PM, DeLange EC, Derendorf H, Elmquist WF, Hammarlund-Udenaes M, Joukhadar C, Kellogg DL, Jr, Lunte CE, Nordstrom CH, Rollema H, Sawchuk RJ, Cheung BW, Shah VP, Stahle L, Ungerstedt U, Welty DF, Yeo H. 2007. AAPS-FDA workshop white paper: microdialysis principles, application, and regulatory perspectives. J Clin Pharmacol 47: 589-603. http://dx.doi.org/10.1177/0091270006299091.
10. Matzneller P, Brunner M. 2011. Recent advances in clinical microdialysis. TrAC Trends Anal Chem 30:1497-1504. http://dx.doi.org/10.1016/j.trac.2011.06.008.
11. Muller M. 2002. Science, medicine, and the future: microdialysis. BMJ 324:588-591. http://dx.doi.org/10.1136/bmj.324.7337.588.
12. Turnidge JD. 1998. The pharmacodynamics of beta-lactams. Clin Infect Dis 27:10-22. http://dx.doi.org/10.1086/514622.
13. AstraZeneca. Zinforo. Summary of product characteristics. AstraZeneca, London, United Kingdom.
14. European Committee on Antimicrobial Susceptibility Testing. 2014. Breakpoint tables for interpretation of MICs and zone diameters, version 4.0.
15. Biedenbach DJ, Alm RA, Lahiri SD, Reiszner E, Hoban DJ, Sahm DF, Bouchillon SK, Ambler JE. 2015. In vitro activity of ceftaroline against Staphylococcus aureus isolated in 2012 from Asia-Pacific countries as part of the AWARE Surveillance Program. Antimicrob Agents Chemother 60: 343-347. http://dx.doi.org/10.1128/AAC.01867-15.
16. Biedenbach DJ, Hoban DJ, Reiszner E, Lahiri SD, Alm RA, Sahm DF, Bouchillon SK, Ambler JE. 2015. In vitro activity of ceftaroline against Staphylococcus aureus isolates collected in 2012 from Latin American countries as part of the AWARE Surveillance Program. Antimicrob Agents Chemother 59:7873-7877. http://dx.doi.org/10.1128/AAC.01833-15.
17. Farrell DJ, Flamm RK, Sader HS, Jones RN. 2013. Spectrum and potency of ceftaroline tested against leading pathogens causing skin and soft-tissue infections in Europe (2010). Int J Antimicrob Agents 41:337-342. http://dx.doi.org/10.1016/j.ijantimicag.2012.12.013.
18. Flamm RK, Sader HS, Jones RN. 2014. Ceftaroline activity tested against contemporary Latin American bacterial pathogens (2011). Braz J Infect Dis 18:187-195. http://dx.doi.org/10.1016/j.bjid.2013.11.005.
19. Flamm RK, Sader HS, Jones RN. 2013. Spectrum and potency of ceftaroline against leading pathogens causing community-acquired respiratory tract and skin and soft tissue infections in Latin America, 2010. Braz J Infect Dis 17:564-572. http://dx.doi.org/10.1016/j.bjid.2013.02.008.
20. Karlowsky JA, Biedenbach DJ, Bouchillon SK, Iaconis JP, Reiszner E, Sahm DF. 2016. In vitro activity of ceftaroline against bacterial pathogens isolated from skin and soft tissue infections in Europe, Russia and Turkey in 2012: results from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance programme. J Antimicrob Chemother 71:162-169. http://dx.doi.org/10.1093/jac/dkv311.
21. Justo JA, Mayer SM, Pai MP, Soriano MM, Danziger LH, Novak RM, Rodvold KA. 2015. Pharmacokinetics of ceftaroline in normal body weight and obese (classes I, II, and III) healthy adult subjects. Antimicrob Agents Chemother 59:3956-3965. http://dx.doi.org/10.1128/AAC.00498-15.
22. Riccobene TA, Su SF, Rank D. 2013. Single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjects. Antimicrob Agents Chemother 57:1496-1504. http://dx.doi.org/10.1128/AAC.02134-12.
23. Andes D, Craig WA. 2006. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob Agents Chemother 50:1376-1383. http://dx.doi.org/10.1128/AAC.50.4.1376-1383.2006.
24. Andes D, Craig W. 2014. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Author correction. Antimicrob Agents Chemother 58:2489. http://dx.doi.org/10.1128/AAC.00134-14.
25. MacGowan AP, Noel AR, Tomaselli S, Bowker KE. 2013. Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection. Antimicrob Agents Chemother 57: 2451-2456. http://dx.doi.org/10.1128/AAC.01386-12.
26. Singh R, Almutairi M, San Martin M, Chen A, Ambler JE. 2015. Evaluation of ceftaroline pharmacokinetic/pharmacodynamic (PK/PD) target against diverse characterized clinical isolates of Staphylococcus aureus isolates in an in vitro hollow-fibre infection model, abstr O138. Abstr 25th Eur Conf Clin Microbiol Infect Dis, Copenhagen, Denmark.
27. Li J, Singh R, Ambler JE. 2015. Probability of target attainment (PTA) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoint for ceftaroline fosamil 600 mg every 12 h and every 8 h against Staphylococcus aureus, abstr P1384. Abstr 55th Intersci Conf Antimicrob Agents Chemother, San Diego, CA. American Society for Microbiology, Washington, DC.
28. Mouton JW, Theuretzbacher U, Craig WA, Tulkens PM, Derendorf H, Cars O. 2008. Tissue concentrations: do we ever learn? J Antimicrob Chemother 61:235-237. http://dx.doi.org/10.1093/jac/dkm476.
29. Joukhadar C, Frossard M, Mayer BX, Brunner M, Klein N, Siostrzonek P, Eichler HG, Muller M. 2001. Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med 29:385-391. http://dx.doi.org/10.1097/00003246-200102000-00030.
30. Ho TT, Cadena J, Childs LM, Gonzalez-Velez M, Lewis JS, II. 2012. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother 67: 1267-1270. http://dx.doi.org/10.1093/jac/dks006.
31. Jacqueline C, Amador G, Batard E, Le Mabecque V, Miegeville AF, Biek D, Caillon J, Potel G. 2011. Comparison of ceftaroline fosamil, daptomycin and tigecycline in an experimental rabbit endocarditis model caused by methicillin-susceptible, methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. J Antimicrob Chemother 66:863-866. http://dx.doi.org/10.1093/jac/dkr019.
32. Croisier-Bertin D, Piroth L, Charles PE, Larribeau A, Biek D, Ge Y, Chavanet P. 2011. Ceftaroline versus ceftriaxone in a highly penicillin-resistant pneumococcal pneumonia rabbit model using simulated human dosing. Antimicrob Agents Chemother 55:3557-3563. http://dx.doi.org/10.1128/AAC.01773-09.